Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03429413 · ClinicalTrials.gov registry record · NA
Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial
A NA study, sponsored by University of Florida.
- Not yet
- Registry status
- NA
- Development phase
- 1,296
- Enrollment target
NCT03429413: Clinical Trial NA study, sponsored by University of Florida.
NCT03429413 is a NA study that has not yet begun recruiting, run by University of Florida. The registered enrollment target is 1,296 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03429413, a NA study, has not yet begun recruiting, sponsored by University of Florida.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 1,296 participants
- Enrollment target
Study Summary
Human papillomavirus (HPV) vaccines have potential to prevent an average of 26,900 cancer cases each year in the United States, but vaccine coverage rates remain low. The study team has developed an electronic application (app), Protect Me 4, to help parents and providers assess and have more productive conversations about needed vaccines. The specific aims of this study are to: (1) evaluate the feasibility of implementing Protect Me 4, and (2) estimate preliminary efficacy of Protect Me 4 to increase HPV vaccine initiation (receipt of first dose).
Primary Outcome
Goal will be to have 80% of the parents of 11-12 year olds offered the Protect Me 4 app.
Interventions
- BEHAVIORAL Protect Me 4 Application + External Quality Improvement Support
- BEHAVIORAL Protect Me 4 Application Alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,296 participants |
| Start Date | 2026-09-15 |
| Est. Completion | 2027-09-15 |
| Phase | NA |
What is known before NCT03429413 opens enrollment
NCT03429413 is an interventional study that assigns participants to a tested intervention. Its 1,296 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Protect Me 4 Application + External Quality Improvement Support is the first listed.
NCT03429413 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03429413 about?
NCT03429413 is a clinical study titled "Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial". Human papillomavirus (HPV) vaccines have potential to prevent an average of 26,900 cancer cases each year in the United States, but vaccine coverage rates remain low. The study team has developed an electronic application (app), Protect Me 4, to help parents and providers assess and have more produc...
What is the current status of trial NCT03429413?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 1,296 participants. The study started on 2026-09-15. Estimated completion is 2027-09-15.
What interventions are being tested in trial NCT03429413?
The interventions under investigation include: Protect Me 4 Application + External Quality Improvement Support (BEHAVIORAL), Protect Me 4 Application Alone (BEHAVIORAL).
Who is sponsoring clinical trial NCT03429413?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03429413's enrollment target sits among peer trials
1,296 78th of 2000 higher than 1,923 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05812807 · 1,295 participants · Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
- NCT04792684 · 1,300 participants
Collection of Samples USOPTIVAL Study
- NCT05166694 · 1,300 participants · NA
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI